<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34984714</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2125</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>88</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of clinical pharmacology</Title>
          <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients.</ArticleTitle>
        <Pagination>
          <StartPage>2802</StartPage>
          <EndPage>2813</EndPage>
          <MedlinePgn>2802-2813</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15212</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To determine the safety and efficacy-potential of inhaled nebulised unfractionated heparin (UFH) in the treatment of hospitalised patients with COVID-19.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective, uncontrolled multicentre single-arm case series of hospitalised patients with laboratory-confirmed COVID-19, treated with inhaled nebulised UFH (5000 IU q8h, 10 000 IU q4h, or 25 000 IU q6h) for 6 ± 3 (mean ± standard deviation) days. Outcomes were activated partial thromboplastin time (APTT) before treatment (baseline) and highest-level during treatment (peak), and adverse events including bleeding. Exploratory efficacy outcomes were oxygenation, assessed by ratio of oxygen saturation to fraction of inspired oxygen (FiO<sub>2</sub> ) and FiO<sub>2</sub> , and the World Health Organisation modified ordinal clinical scale.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 98 patients included. In patients on stable prophylactic or therapeutic systemic anticoagulant therapy but not receiving therapeutic UFH infusion, APTT levels increased from baseline of 34 ± 10 seconds to a peak of 38 ± 11 seconds (P &lt; .0001). In 3 patients on therapeutic UFH infusion, APTT levels did not significantly increase from baseline of 72 ± 20 to a peak of 84 ± 28 seconds (P = .17). Two patients had serious adverse events: bleeding gastric ulcer requiring transfusion and thigh haematoma; both were on therapeutic anticoagulation. Minor bleeding occurred in 16 patients, 13 of whom were on therapeutic anticoagulation. The oxygen saturation/FiO<sub>2</sub> ratio and the FiO<sub>2</sub> worsened before and improved after commencement of inhaled UFH (change in slope, P &lt; .001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Inhaled nebulised UFH in hospitalised patients with COVID-19 was safe. Although statistically significant, inhaled nebulised UFH did not produce a clinically relevant increase in APTT (peak values in the normal range). Urgent randomised evaluation of nebulised UFH in patients with COVID-19 is warranted and several studies are currently underway.</AbstractText>
          <CopyrightInformation>© 2022 British Pharmacological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Haren</LastName>
            <ForeName>Frank M P</ForeName>
            <Initials>FMP</Initials>
            <Identifier Source="ORCID">0000-0001-8037-4229</Identifier>
            <AffiliationInfo>
              <Affiliation>Australian National University, College of Health and Medicine, Canberra, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Saint George Hospital, Sydney, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Loon</LastName>
            <ForeName>Lex M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Australian National University, College of Health and Medicine, Canberra, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steins</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Australian National University, College of Health and Medicine, Canberra, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smoot</LastName>
            <ForeName>Thomas L</ForeName>
            <Initials>TL</Initials>
            <Identifier Source="ORCID">0000-0002-6188-2217</Identifier>
            <AffiliationInfo>
              <Affiliation>Frederick Health Hospital, Frederick, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sas</LastName>
            <ForeName>Caitlin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Frederick Health Hospital, Frederick, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Staas</LastName>
            <ForeName>Sabrina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Frederick Health Hospital, Frederick, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vilaseca</LastName>
            <ForeName>Alicia B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbera</LastName>
            <ForeName>Ruben A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vidmar</LastName>
            <ForeName>Gustavo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beccari</LastName>
            <ForeName>Hugo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popilevsky</LastName>
            <ForeName>Frida</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daribayeva</LastName>
            <ForeName>Eleonora</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatesan</LastName>
            <ForeName>Bhuvaneshwari</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mozes</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Postel</LastName>
            <ForeName>Rachel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popilevski</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Intensive Care Unit, Coney Island Hospital, Brooklyn, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Webb</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-8109-1877</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology, School of Cardiovascular Medicine &amp; Sciences, King's College, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nunes</LastName>
            <ForeName>Quentin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laffey</LastName>
            <ForeName>John G</ForeName>
            <Initials>JG</Initials>
            <Identifier Source="ORCID">0000-0002-1246-9573</Identifier>
            <AffiliationInfo>
              <Affiliation>Anaesthesia and Intensive Care Medicine, School of Medicine, and Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland Galway, Galway, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesia, University Hospital Galway, Saolta Hospital Group, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Artigas</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Critical Center, Corporació Universitaria Sanitaria Parc Tauli, CIBER Enfermedades Respiratorias, Autonomous University of Barcelona, Sabadell, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Roger</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Critical Care Medicine, St Vincent's Hospital, Melbourne, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dixon</LastName>
            <ForeName>Barry</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Critical Care Medicine, St Vincent's Hospital, Melbourne, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Richardson</LastName>
            <ForeName>Alice</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Statistical Consulting Unit, Australian National University, Canberra, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoon</LastName>
            <ForeName>Hwan-Jin</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Statistical Consulting Unit, Australian National University, Canberra, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Page</LastName>
            <ForeName>Clive</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Sackler Institute of Pulmonary Pharmacology, King's College London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>7503323</NlmUniqueID>
        <ISSNLinking>0306-5251</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-49-6</RegistryNumber>
          <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010314" MajorTopicYN="N">Partial Thromboplastin Time</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">case series</Keyword>
        <Keyword MajorTopicYN="N">inhaled heparin</Keyword>
        <Keyword MajorTopicYN="N">nebulised heparin</Keyword>
        <Keyword MajorTopicYN="N">pandemic</Keyword>
        <Keyword MajorTopicYN="N">respiratory failure</Keyword>
        <Keyword MajorTopicYN="N">unfractionated heparin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34984714</ArticleId>
        <ArticleId IdType="doi">10.1111/bcp.15212</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-1242.</Citation>
        </Reference>
        <Reference>
          <Citation>Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama. 2020;323(20):2052-2059.</Citation>
        </Reference>
        <Reference>
          <Citation>Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.</Citation>
        </Reference>
        <Reference>
          <Citation>Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;323(16):1574-1581.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-943.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-1069.</Citation>
        </Reference>
        <Reference>
          <Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.</Citation>
        </Reference>
        <Reference>
          <Citation>van Haren FMP, Page C, Laffey JG, et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care. 2020;24(1):454.</Citation>
        </Reference>
        <Reference>
          <Citation>Conzelmann C, Müller JA, Perkhofer L, et al. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. Clin Med. 2020;20(6):e218-e221.</Citation>
        </Reference>
        <Reference>
          <Citation>Ball L, Schultz MJ, Pelosi P. Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia. The Lancet. Respir Med. 2021;9(4):321-322.</Citation>
        </Reference>
        <Reference>
          <Citation>Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183:1043-1057.e15.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwon PS, Oh H, Kwon SJ, et al. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 2020;6(1):50.</Citation>
        </Reference>
        <Reference>
          <Citation>Mycroft-West CJ, Su D, Pagani I, et al. Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin. Thromb Haemost. 2020;120(12):1700-1715.</Citation>
        </Reference>
        <Reference>
          <Citation>Tree JA, Turnbull JE, Buttigieg KR, et al. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol. 2021;178(3):626-635.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care. 2010;14(5):445.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. Intensive Care Med. 2008;34(7):1216-1223.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010;14(5):R180.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon B, Smith R, Santamaria JD, et al. A trial of nebulised heparin to limit lung injury following cardiac surgery. Anaesth Intensive Care. 2016;44(1):28-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon B, Smith RJ, Campbell DJ, et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(4):360-372.</Citation>
        </Reference>
        <Reference>
          <Citation>van Haren FMP, Richardson A, Yoon H-J, et al. INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. Br J Clin Pharmacol. 2021;1-17.</Citation>
        </Reference>
        <Reference>
          <Citation>Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 2014;67(1):46-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e197.</Citation>
        </Reference>
        <Reference>
          <Citation>Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the Sp o 2 /F io 2 ratio and the Pa o 2 /F io 2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132(2):410-417. https://doi.org/10.1378/chest.07-0617</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander SPH, Kelly E, Mathie A, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 2019;176(S1):S1-S20.</Citation>
        </Reference>
        <Reference>
          <Citation>Dunning MB, Fischbach FT. A manual of laboratory and diagnostic tests. 8th Editon ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Pagana KD, Pagana TJ. Mosby's manual of diagnostic and laboratory tests. 6th Editon ed. St. Louis, Missouri: Elsevier; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Chimenti L, Camprubi-Rimblas M, Guillamat-Prats R, et al. Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury. Thromb Haemost. 2017;117(11):2125-2134.</Citation>
        </Reference>
        <Reference>
          <Citation>Markart P, Nass R, Ruppert C, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(3):161-172.</Citation>
        </Reference>
        <Reference>
          <Citation>Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J. 2002;19(4):606-610.</Citation>
        </Reference>
        <Reference>
          <Citation>Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. Pulm Pharmacol Ther. 2018;48:88-96.</Citation>
        </Reference>
        <Reference>
          <Citation>Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J. 2006;27(2):354-358.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
